Breast cancer represents the most commonly diagnosed cancer while neoadjuvant and
adjuvant chemotherapies are extensively used in order to reduce tumor development and …

Cancer cachexia—cancer-associated body weight and muscle loss—is a significant
predictor of mortality and morbidity in cancer patients across a variety of cancer types …

The majority of cancers are associated to cachexia, a severe form of weight loss mostly
accounted for by skeletal muscle wasting. Cancer patients are often treated with …

The management of cancer patients is frequently complicated by the occurrence of
cachexia. This is a complex syndrome that markedly impacts on quality of life as well as on …

Skeletal muscle weakness is a debilitating consequence of many malignancies. Muscle
weakness has a negative impact on both patient wellbeing and outcome in a range of …

How breast cancer and its treatments affect skeletal muscle is not well defined. To address
this question, we assessed skeletal muscle structure and protein expression in 13 women …

Cancer cachexia is a severe and disabling clinical condition that frequently accompanies
the development of many types of cancer. Muscle wasting is the hallmark of cancer cachexia …

Cancer cachexia is a systemic hypoanabolic and catabolic syndrome that diminishes the
quality of life of cancer patients, decreases the efficiency of therapeutic strategies and …

Muscle wasting is the most important phenotypic and clinical feature of cancer cachexia, and
the principal cause of impaired physical function, fatigue, and respiratory complications …

Background Low muscle in cancer is associated with an increase in treatment‐related
toxicities and is a predictor of cancer‐related and all‐cause mortality. The mechanisms of …